Pharmacelera – Find larger chemical diversity |

Machine Learning partnership to accelerate discovery of novel drugs

CCDC and Pharmacelera combine virtual screening and machine learning expertise to help scientists accelerate drug discovery Barcelona and Cambridge, UK, 26th June 2019. The Cambridge Crystallographic Data Centre (CCDC) and Pharmacelera have reached an agreement to perform a joint research project to reinforce the results obtained by structure-based in-silico technologies via ligand-based tools. GOLD, CCDC’s docking software used…

Agreement with Universitat Autònoma de Barcelona (UAB) in drug discovery for Parkinson disease

The Universitat Autònoma de Barcelona (UAB) and Pharmacelera have reached an agreement to perform a research project in the area of Parkinson based on the work led by Dr. Salvador Ventura and developed at Institut de Biotecnologia i Biomedicina (IBB). PharmScreen®, Pharmacelera’s flagship software, will be used to perform screening campaigns in huge virtual libraries…

Pharmacelera participates in the SME Instrument Phase I program

Pharmacelera has been awarded an SME Phase I grant from the European Commission for its MolPredict project. The EU received 2009 requests in the call where Pharmacelera submitted its proposal and it decided to support 257 small and medium-sized companies (SMEs) from 31 countries (a 12.8% acceptance rate) who aim to get their innovations faster…

Blog

Machine Learning partnership to accelerate discovery of novel drugs

Agreement with Universitat Autònoma de Barcelona (UAB) in drug discovery for Parkinson disease

Empowering Biotechnology sector in the Bioregion of Catalonia

Pharmacelera participates in the SME Instrument Phase I program

Follow us!